Fund Story 2: The Return of Woody – Pt 1
And as the years go by Our friendship will never die You’re gonna see it’s our destiny …
Woodford fund suspension
-
-
Terry Smith says Woodford needs to publicly apologise and own up to mistakes to earn redemption
Fundsmith Equity manager is a believer in human redemption but only after a period of ‘painful self-examination’
-
FCA accused of being ‘on the back foot’ in response to Woodford comeback
Regulator to work with the Jersey Financial Services Commission to share information on any applications
-
Neil Woodford stock slashed 70% hitting fund and trust investors
Schroder UK Public Private Trust reckons the cash exit of unnamed investors means fundamentals not reflected in valuation
-
Link offloads remaining Woodford healthcare assets to Acacia
But £192m remains in the former Woodford Equity Income fund
-
Woodford wind-up cost has spiked £116k since end of September
Comes as Link prepares to make fourth repayment of £100m to investors in the next few days
-
Campaign group launches for Woodford Equity Income investors seeking redress
#JusticeForWoodfordInvestors comes as Harcus Parker prepares to file its case at court
-
Former Woodford healthcare stock grateful to finally land new owner
Link Fund Solutions had held a 12% stake in Sensyne Health
-
Link receives first formal letter triggering litigation over Woodford debacle
ACD stands accused of allowing excessive investments in inappropriate assets
-
Mark Dampier to retire from Hargreaves Lansdown within days
Platform’s head of research had been tarnished for his championing of Neil Woodford
-
Ex-Woodford trust handed to Schroders could see 20% uplift if stars align
Stifel has a contrarian buy rating on the Schroders UK Public Private investment trust
-
Former Woodford stock sold by Link reports positive antibody trial
Kymab announced a successful Phase 2a for its dermatitis antibody